The Drug-Induced Respiratory Disease Website
May lead to ED visit (PMID 29601310)
Publications
Theophylline for Attenuating Ticagrelor-Related Dyspnea.
Arquivos brasileiros de cardiologia 2021 07;117;146-148 — 2021 07 — 146-148
Di Filippo C, Caniato F, Cappelli F, Mattesini A, Meucci F, Sori A, Stolcova M, Agostini C, Bernardo P, Di Mario C
Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.
Journal of cardiovascular medicine (Hagerstown, Md.) 2021 04 01;22;317-319 — 2021 04 01 — 317-319
The risk of dyspnea in patients treated with third-generation P2Y inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials.
BMC cardiovascular disorders 2020 Mar 17;20;140 — 2020 Mar 17 — 140
Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann FJ, Plante S, Hernández Antolin R, Jambrik Z, Gelev V, Brunel P, Konteva M, Beygui F, Morelle JF, Filipiak KJ, van Geuns RJ, Soliman O, Tijssen J, Rademaker-Havinga T,
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial.
European heart journal. Cardiovascular pharmacotherapy 2019 Dec 09;; — 2019 Dec 09
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA,
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
The New England journal of medicine 2019 Oct 03;381;1309-1320 — 2019 Oct 03 — 1309-1320
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.
BMC cardiovascular disorders 2018 11 29;18;217 — 2018 11 29 — 217
Ticagrelor-related late-onset dyspnea as cause of emergency department visit: a 3-year outpatient study.
Journal of cardiovascular medicine (Hagerstown, Md.) 2018 Jun;19;284-289 — 2018 Jun — 284-289
Alexopoulos D, Xanthopoulou I, Perperis A, Goudevenos J, Hamilos M, Sitafidis G, Kanakakis I, Vavouranakis M, Giannopoulos G, Barampoutis N, Deftereos S, Lekakis J
Dyspnea in patients treated with P2Y receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry.
Platelets 2017 Nov;28;691-697 — 2017 Nov — 691-697
Successful Reversal of Bradycardia and Dyspnea With Aminophylline After Ticagrelor Load.
Journal of pharmacy practice 2018 Feb;31;112-114 — 2018 Feb — 112-114
Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Špinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
JAMA cardiology 2016 Jul 01;1;425-32 — 2016 Jul 01 — 425-32
Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D,
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Journal of the American Heart Association 2015 Oct 09;4;e002490 — 2015 Oct 09 — e002490
Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr.
American heart journal 2015 Sep;170;465-70 — 2015 Sep — 465-70
Sánchez-Galian MJ, Flores-Blanco PJ, López-Cuenca A, Gómez-Molina M, Guerrero-Pérez E, Cambronero-Sánchez F, Sánchez-Martínez M, Valdés M, Manzano-Fernández S
Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn.
International journal of cardiology 2015;187;517-8 — 2015 — 517-8
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine
Long-term use of ticagrelor in patients with prior myocardial infarction.
The New England journal of medicine 2015 May 07;372;1791-800 — 2015 May 07 — 1791-800
Ticagrelor-related dyspnea: an underestimated and poorly managed event?
International journal of cardiology 2015 Jan 20;179;238-9 — 2015 Jan 20 — 238-9
Gaubert M, Laine M, Richard T, Fournier N, Gramond C, Bessereau J, Mokrani Z, Bultez B, Chelini V, Barnay P, Maillard L, Paganelli F, Bonello L
Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients.
International journal of cardiology 2014 Apr 15;173;120-1 — 2014 Apr 15 — 120-1
Potential role of endogenous adenosine in ticagrelor-induced dyspnea.
Pharmacotherapy 2013 Aug;33;882-7 — 2013 Aug — 882-7
Why does ticagrelor induce dyspnea?
Thrombosis and haemostasis 2012 Dec;108;1031-6 — 2012 Dec — 1031-6
'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' - a hypothesis that remains unproven.
Thrombosis and haemostasis 2012 Dec;108;1028-30 — 2012 Dec — 1028-30
Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel.
Thrombosis and haemostasis 2012 Dec;108;1024-7 — 2012 Dec — 1024-7
Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin L
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
European heart journal 2011 Dec;32;2945-53 — 2011 Dec — 2945-53
Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel PA,
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Journal of the American College of Cardiology 2010 Jul 13;56;185-93 — 2010 Jul 13 — 185-93
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, , Freij A, Thorsén M
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
The New England journal of medicine 2009 Sep 10;361;1045-57 — 2009 Sep 10 — 1045-57
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Cardiovascular therapeutics 2009;27;259-74 — 2009 — 259-74